KiOnutrime®-CG for Cardiovascular Health

KiOnutrime®-CG is an innovative ingredient that supports healthy arteries as a new approach to cardiovascular health.

This technology supports the body’s natural antioxidant systems and mechanisms for managing free radicals within the cardiovascular system. KiOnutrime®-CG is a high-purity natural ingredient that has shown effects on oxidation in multiple clinical studies.

Oxidised-LDL is a newly emerging biomarker for cardiovascular health that is clearly related to the atherosclerosis.

KiOnutrime®-CG is an all-natural, self-affirmed GRAS ingredient that is appropriate for use in vegetarian, Kosher and Halal products.

Product overview:

  • KiOnutrime®-CG supports clean and healthy arteries.
  • Supports oxidative balance important for heart and artery health.
  • Reduce the risk of atherosclerosis and cardiovascular diseases
  • Enables stronger resistance to cardiovascular diseases through better general antioxidant activity
  • Provides protection from damage caused by free radicals
  • Supports already healthy levels of LDL cholesterol.
  • Natural, non-animal, self-affirmed GRAS, non-GMO Chitin-glucan.
  • EU Commission approval as a novel food ingredient.
  • Manufactured to ISO and HACCP guidelines.
  • Safe and appropriate for use in vegetarian, Kosher and Halal products.

The Science behind KiOnutrime®-CG

KiOnutrime®-CG provides a full package of studies, including a double-blind randomised, placebo-controlled multi-centric clinical trial:

KiOnutrime®-CG Effects on OxLDL: a Randomised Controlled Trial

Abstract: The primary objective of this study was to evaluate the efficacy of Chitin-Glucan (CG) alone and in combination with a potentially anti-inflammatory olive oil (OO) extract, for reducing OxLDL in subjects with borderline to high LDL cholesterol (LDL-C) levels. This six week, randomised, double-blind, placebo-controlled study of a novel, insoluble fibre derived from the Aspergillus niger mycelium, CG, evaluated 130 subjects free of diabetes mellitus with fasting LDL-C 3.37–4.92 mmol/l and glucose p6.94 mmol/l. Participants were randomly assigned to receive CG (4.5 g/day; n¼33), CG (1.5 g/day; n¼32), CG (1.5 g/day) plus OO extract (135 mg/day; n¼30), or matching placebo (n¼35).

Results found that the administration of 4.5 g/day CG for six weeks significantly reduced OxLDL compared with the placebo (P¼0.035). At the end of the study, CG was associated with lower LDL-C levels relative to placebo, although this difference was statistically significant only for the CG 1.5 g/day group (P¼0.019). CG did not significantly affect high-density lipoprotein cholesterol, triglycerides, glucose, insulin or F2-isoprostane levels. Adverse events did not substantively differ between treatments and the placebo. In conclusion, this six week study, CG (4.5 g/day) reduced OxLDL, an effect that might influenceaffect the risk for atherosclerosis.

Full published article: HE Bays, JL Evans, KC Maki, M Evans, V Maquet, R Cooper and JW Anderson. Chitin-Glucan fibre effects on oxidised low-density lipoprotein: a randomised controlled trial. European Journal of Clinical Nutrition (2012), 1–6.